Nā ʻano hana
Ka palena ʻike: 5ng/mL ;
Laina Linear: 5.00～400.00 ng/mL;
Koefficient huikau laina R ≥0.990;
Ka pololei: i loko o ka puʻupuʻu CV ʻo ≤15%;ma waena o nā pūʻulu CV he ≤20%;
Pono: ʻaʻole e ʻoi aku ka ʻae ʻana o nā hopena ana ma mua o ± 15% ke hoʻāʻo ʻia ka calibrator pololei.
1. E mālama i ka mea ʻike maka ma 2~30 ℃.Kūpaʻa ka buffer a hiki i 18 mahina.
2. E kūʻai i ka cassette hōʻike Aehealth Ferritin Rapid Quantitative ma 2~30 ℃, a hiki i ka 18 mahina.
3. Pono e hoʻohana i ka pahu hoʻāʻo i loko o 1 hola ma hope o ka wehe ʻana i ka ʻeke.
He lālā ʻo ST2 o ka ʻohana like ʻole Toll-like/interleukin-1 (interleukin-1, IL-1).ʻO IL-33 kona ligand hana kūikawā a hūnā ʻia e nā cardiomyocytes a me nā fibroblasts.ʻElua huahana o ka hōʻike gene: transmembrane ST2 (ST2L) a me sST2.Loaʻa iā ST2L ʻekolu mau kikowaena immunoglobulin extracellular, ʻoiai ʻo sST2 nele i ka transmembrane a me ka intracellular receptor domain.Hoʻopaʻa lākou i ka ligand maʻamau IL-33 a pāʻani i kahi kuleana ola.Loaʻa i ke ala hōʻailona ST2L a me IL-33 nā hopena cardioprotective e like me ka hypertrophy anti-cardiomyocyte, myocardial fibrosis a me ka anti-atherosclerosis.Ke piʻi aʻe ka puʻuwai, piʻi ka huna ʻana o sST2, a ʻo ka sST2 i hoʻonui ʻia e pale i ka IL-33 mai ka hui ʻana me ST2L, a laila e pale aku i ka hopena cardioprotective o ke ala hōʻailona IL-33/ST2L.Ua manaʻo ʻia ʻo ka sST2 he mea hoʻoponopono pathogenic o ka hypertrophy cardiomyocyte a me ka myocardial fibrosis.ʻO ka hoʻoholo nui o nā pae sST2 hiki ke hāʻawi i nā kauka i kahi mea hana kūpono e kōkua i ka loiloi ʻana i ka hāʻule ʻole o ka naʻau.